Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics of methotrexate.

Maja Krajinovic1, Albert Moghrabi

  • 1Université de Montréal, Service d'Hématologie-Oncologie, Centre de Recherche, Hôpital Sainte-Justine Département de Pédiatrie, 3175 Côte St Catherine, Montreal, Quebec, H3T 1C5, Canada. maja.krajinovic@umontreal.ca.

Pharmacogenomics
|October 8, 2004
PubMed
Summary

Methotrexate (MTX) is effective for various conditions but can cause resistance or side effects. Genetic variations in folate pathway genes can predict patient response and toxicity to MTX therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT.

Bone marrow transplantation·2026
Same author

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Clinical pharmacology and therapeutics·2026
Same author

Novel Genetic Risk Factor Identified for L-Asparaginase-Induced Pancreatitis in Pediatric Patients With Cancer.

Pediatric blood & cancer·2026
Same author

Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.

Blood advances·2026
Same author

IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

Leukemia research·2026
Same author

Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia.

Cancer research communications·2025

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Oncology

Background:

  • Methotrexate (MTX) is a widely used drug for malignancies and inflammatory conditions.
  • Patient response to MTX varies due to potential drug resistance and toxic side effects.
  • MTX efficacy is linked to folate metabolism, involving folate-dependent enzymes.

Purpose of the Study:

  • To explore the role of genetic variations in predicting MTX efficacy and toxicity.
  • To review candidate genes and their interactions influencing patient response to MTX.
  • To highlight the potential for personalized MTX therapy based on genetic profiles.

Main Methods:

  • Review of existing studies on genetic variants and MTX response, primarily in leukemia and rheumatoid arthritis.
  • Analysis of genetic polymorphisms in folate pathway genes, including methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TYMS).

Related Experiment Videos

  • Discussion of gene-gene interactions as potential predictors of MTX outcomes.

    • Main Results:

    • Specific genetic variants in genes like MTHFR and TYMS have shown predictive value for MTX response.
    • Individual gene effects and combined gene-gene interactions can influence patient sensitivity and outcomes.
    • Genetic profiling offers a promising approach to tailor MTX treatment.

    Conclusions:

    • Genetic factors significantly modulate patient response to Methotrexate therapy.
    • Personalized medicine approaches, guided by pharmacogenetics, can optimize MTX treatment strategies.
    • Further research into gene-gene interactions is crucial for comprehensive MTX therapy prediction.